Zobrazeno 1 - 10
of 25
pro vyhledávání: ''
Autor:
Tomislav Dragovich, Leonard L. Gunderson, Richard Swanson, Steven R. Alberts, R. M. Goldberg, Georg A. Bjarnason, Jeffrey A. Meyerhardt, Donna Niedzwiecki, J. E. Tepper, David J Berg, Charles S. Fuchs, Xing Ye, Alan P. Venook, Christopher G. Willett, Eileen M. O'Reilly, Kristen K. Ciombor, Daniel G. Haller, Harvey J. Mamon, Robert J. Mayer, David H. Ilson, Peter C. Enzinger
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 32
Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815b81863611fe5699b7d3975a5bb69d
https://europepmc.org/articles/PMC5678342/
https://europepmc.org/articles/PMC5678342/
Autor:
David Planchard, Martin Reck, N. Morsli, Paul Taylor, Natasha B Leighl, José Barrueco, Federica Grosso, Silvia Novello, Sanjay Popat, Anna K. Nowak, Laurent Greillier, Giorgio V. Scagliotti, Thomas John, Mark A. Socinski, Nicola Steele, Jens Benn Sørensen, Arsene Bienvenu Loembe, Ute von Wangenheim
Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here. Patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b3b67a7c511c65e68c6752a93e01b4b
http://hdl.handle.net/10044/1/55960
http://hdl.handle.net/10044/1/55960
Autor:
Jordan Berlin, Steven J. Cohen, David M. Goldenberg, Richard M Goldberg, John L. Marshall, Pamela S. Simpson, Alexander Starodub, Christopher H. Lieu, Michael J. Guarino, Robert M. Sharkey, Serengulam V. Govindan, William A. Wegener, Wells A. Messersmith, J. Randolph Hecht, Efrat Dotan
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 29
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 29
Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::149bbb5695ad0619ea8e03e548c08004
https://europepmc.org/articles/PMC8259133/
https://europepmc.org/articles/PMC8259133/
Autor:
Noelle K. LoConte, Edward M. Wolin, Helen X. Chen, Katherine A. Guthrie, James C. Yao, Jonathan R. Strosberg, Bassam I. Mattar, Shannon McDonough, Howard S. Hochster, Cesar A Moran, Robert R. McWilliams, Charles D. Blanke, Matthew H. Kulke, Jennifer A. Chan
Purpose Treatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs. Patients and Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8d5f337f30d6698e79a67ab6f1976d2
https://europepmc.org/articles/PMC5455764/
https://europepmc.org/articles/PMC5455764/
Autor:
Rakhshandra Talpur, Audra L. Clos, Madeleine Duvic, Pamela Gangar, Michael T. Tetzlaff, Dawen Sui
Purpose Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30+ receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30+ cutaneous T-cell lymphomas. Patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da822c95024641b2c8878ac46b0d53f8
https://europepmc.org/articles/PMC4737859/
https://europepmc.org/articles/PMC4737859/
Autor:
Anna Skowronska, Frankie Mo, Sarah Berhane, Chiaki Kagebayashi, D. Palmer, Hidenori Toyoda, Bruno Sangro, Stephen L. Chan, Mercedes Iñarrairaegui, James O'Beirne, Paul B.S. Lai, Richard Fox, Takashi Kumada, M Teng, Winnie Yeo, Helen L. Reeves, Toshifumi Tada, Rebecca A. Miksad, Philip J. Johnson, Shinji Satomura
Purpose Most patients with hepatocellular carcinoma (HCC) have associated chronic liver disease, the severity of which is currently assessed by the Child-Pugh (C-P) grade. In this international collaboration, we identify objective measures of liver f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e52e58f6daf4409acc0b80dc4305c47
https://europepmc.org/articles/PMC4322258/
https://europepmc.org/articles/PMC4322258/
Autor:
Douglas Adkins, Andrew Eugene Hendifar, Damon R. Reed, Brian A. Van Tine, Lee D. Cranmer, Stew Kroll, Sant P. Chawla, Kristen N. Ganjoo, James E. Butrynski, Scott H. Okuno
Purpose TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is preferentially activated in hypoxic conditions. This phase II study investigated TH-302 in combination with doxorubicin, followed by single-agent TH-302 ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb8a50aab4e904c69088262d990f9499
https://europepmc.org/articles/PMC4588714/
https://europepmc.org/articles/PMC4588714/
Autor:
Marina Konopleva, Sherry Pierce, Yumin Hu, Tapan M. Kadia, Marcos de Lima, Mark Brandt, Deborah McCue, Willie Newsome, Hui Yang, Hagop M. Kantarjian, Gautam Borthakur, Jorge E. Cortes, Francesco Paolo Tambaro, Nebiyou B. Bekele, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Stefan Faderl
Purpose To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Patients and Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb4fe084276bcef5e6da5f5d1f20ef5
https://europepmc.org/articles/PMC4879705/
https://europepmc.org/articles/PMC4879705/
Autor:
Yongli Shuai, John M. Kirkwood, John Cherian, Hussein Tawbi, William E. Gooding, Stergios J. Moschos, Cindy Sander, Ahmad A. Tarhini
Purpose We tested the hypothesis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly synergistic mechanisms would overcome tumor immune tolerance and lead to significant and durable clinical responses. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8443047c3d737990b9882cdab2c6ba7a
https://europepmc.org/articles/PMC3422533/
https://europepmc.org/articles/PMC3422533/
Autor:
Ronald L. Korn, Ramesh K. Ramanathan, Lon Smith, Tao Shi, Mitesh J. Borad, Patrick Soon-Shiong, Hui Zhang, Anirban Maitra, N. V. Rajeshkumar, Daniel A. Laheru, Neil P. Desai, T. E. Wood, Jose Iglesias, Vuong Trieu, Daniel D. Von Hoff, Manuel Hidalgo
Purpose The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate posit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2d96a7a55926856b7d0f836a9d9db5c
https://europepmc.org/articles/PMC3565012/
https://europepmc.org/articles/PMC3565012/